Ismail Demir

Dr. Ismail Demir


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
RARıdvan Aktan
Rıdvan Aktan
HYHayriye Yılmaz
Hayriye Yılmaz
IDIsmail Demir
Ismail Demir
SÖSevgi Özalevli
Sevgi Özalevli

1 January 2021 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
FBFerda Bilgir
Ferda Bilgir
ŞÇŞebnem Çalık
Şebnem Çalık
IDIsmail Demir
Ismail Demir
OBOktay Bilgir
Oktay Bilgir
OBJECTIVE: In this study, we aimed to retrospectively analyze the roles of certain hematological and biochemical parameters in predicting mortality and intensive care unit admission in patients diagnosed with coronavirus disease 2019 (COVID-19). METHODS: We analyzed the complete blood count and biochemical parameters of 186 COVID-19 patients by using the polymerase chain reaction test. Whether these parameters can be used to predict intensive care unit admission and mortality in the COVID-19 patients was investigated. RESULTS: The complete blood count and biochemical parameters of COVID-19 patients and in those admitted to intensive care unit were compared. The red cell distribution width, ferritin, lactate dehydrogenase, D-dimer, C-reactive protein, prothrombin time, and creatinine levels were found to be the most significant parameters. We found that these parameters are significant for predicting not only intensive care unit admission, but also the mortality of the patients admitted to the intensive care unit. CONCLUSIONS: We determined that the most effective parameters to predict intensive care unit admission and mortality in COVID-19 patients are ferritin, lactate dehydrogenase, D-dimer, C-reactive protein, red cell distribution width, creatinine, and intensive care unit. Close monitoring of these parameters and early intervention in alterations are of vital importance.

15 August 2024 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
YSYasin Sahinturk
Yasin Sahinturk
GKGokhan Koker
Gokhan Koker
Nizameddin KocaNizameddin Koca
Nizameddin Koca
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
IDIsmail Demir
Ismail Demir
SUSeyit Uyar
Seyit Uyar
Background/Aims: This awareness study aimed to determine the ultrasound (US) examination rates in relation to US-confirmed metabolic dysfunction-associated fatty liver disease (MAFLD) diagnosis in internal medicine outpatients with type 2 diabetes (T2D) across Türkiye. Materials and Methods: A total of 6283 T2D patients were included in this multicenter retrospective cohort study conducted at 17 internal medicine clinics across Türkiye. The presence and indications for US performed within the last 3 years were recorded along with US-confirmed MAFLD rates, laboratory findings on the day of US, and referral rates. Fibrosis-4 (FIB-4) index was calculated to estimate the risk of advanced liver fibrosis (FIB-4 index ≥ 1.3). Results: Overall, 1731 (27.6%) of 6283 patients had US examination, which revealed MAFLD diagnosis in 69.9% of cases. In addition, 24.4% of patients with US-confirmed MAFLD were at risk of advanced fibrosis (FIB-4 index ≥ 1.3), and the referral rate was 15.5%. Conclusion: In conclusion, our findings emphasize an insufficient MAFLD awareness among clinicians and the likelihood of most of T2D patients to be at risk of living with an unknown status regarding their MAFLD and advanced fibrosis risk. Cite this article as: Şahintürk Y, Köker G, Koca N, et al. Metabolic dysfunction-associated fatty liver disease and fibrosis status in patients with type 2 diabetes treated at internal medicine clinics: Türkiye DAHUDER awareness of fatty liver disease (TR-DAFLD) study. Turk J Gastroenterol. 2024;35(8):643-650.

8 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AKAli Kirik
Ali Kirik
Hilmi Erdem SumbulHilmi Erdem Sumbul
Hilmi Erdem Sumbul
Nizameddin KocaNizameddin Koca
Nizameddin Koca
TKTurkan Pasali Kilit
Turkan Pasali Kilit
SSsibel demiral sezer
sibel demiral sezer
TDTeoman Doğru
Teoman Doğru
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) prevalence data in Türkiye is limited. We aimed to determine the nationwide prevalence of MASLD and advanced hepatic fibrosis risk in subjects with cardiometabolic risk factors (CMRF). Despite recent international consensus redefining fatty liver disease terminology, no nationwide MASLD study has been reported in Türkiye. Methods: This cross-sectional study included 14,371 adults with ≥1 CMRF from 44 centers across 31 cities. MASLD was diagnosed using liver ultrasonography plus cardiometabolic criteria. Advanced fibrosis risk was assessed by fibrosis-4 (FIB-4) score (≥1.3 for ≤65 years; ≥2.0 for >65 years). Logistic regression was used to identify independent predictors of high FIB-4. Results: A total of 61.4% of participants were women, the mean age was 51.3 ± 14.4 years, and the mean BMI was 31.4 ± 6.0 kg/m2. MASLD prevalence was 75.7% (n = 10,873), rising with the number of CMRFs (56.5% with one factor vs. 83.4% with all). The prevalence of high FIB-4 scores was 12.0% overall, being lower in MASLD patients than non-MASLD patients (11.2% vs. 14.4%, p < 0.001). FIB-4 scores decreased with increasing BMI (28.1% underweight vs. 8.7% class III obesity). Male sex, T2DM, and hypertension independently predicted high FIB-4 scores, while smoking, higher BMI, and MASLD were inversely associated. Conclusions: Three-quarters of Turkish adults with CMRF have MASLD. Standard FIB-4 thresholds may underestimate fibrosis risk in obese and smoking populations, underscoring the need for adjusted cut-offs or alternative tools. This study is the first to provide nationwide MASLD prevalence data in Türkiye.

14 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AOAlihan Oral
Alihan Oral
İSİhsan Solmaz
İhsan Solmaz
Nizameddin KocaNizameddin Koca
Nizameddin Koca
UTUlas Serkan Topaloglu
Ulas Serkan Topaloglu
IDIsmail Demir
Ismail Demir
SUSeyit Uyar
Seyit Uyar
Objectives: Obesity is a significant public health concern, as it is associated with the development of numerous chronic diseases. The prevalence of obesity and attendant diseases has been increasing over recent years. This study attempted to ascertain the frequency of chronic diseases in obese patients in Türkiye for the first time on this scale. Methods: A retrospective study was conducted, with patients admitted to the internal medicine outpatient clinics or obesity centers between December 2023 and December 2024 included in this study. Participants were recruited from seven regions, 20 provinces, and 28 centers, and the inclusion criteria were met by those aged 18 years and over with a body mass index (BMI) of 30 kg per square meter (kg/m2) or above. Their status, with respect to chronic diseases, and their anthropometric parameters were documented. Results: The total number of patients was 10,121, with a mean age of 45.2 ± 13.92. Of these, 7222 (71.35%) were female. The prevalence of type 2 diabetes mellitus (T2DM), hypertension (HT), dyslipidemia (DL), coronary artery disease (CAD), obstructive pulmonary disease (OPD), obstructive sleep apnea syndrome (OSAS), and fatty liver disease (FLD) was found to be 35.01%, 78.19%, 12.37%, 10.32%, 5.88%, and 75.12%, respectively. A subsequent analysis of the prevalence of these diseases by region revealed a statistically significant variation between regions (p < 0.001 for all regions). Conclusions: This study represents a substantial contribution to the existing body of knowledge in this field, particularly with regard to the identification of the current chronic disease rate of obese patients in Türkiye.

19 March 2020 in Family Practice and Palliative Care
Verified
Journal Article
Open access
PDF file
IDIsmail Demir
Ismail Demir
MYMuammer Yücel
Muammer Yücel
Introduction: Sepsis is defined as life-threatening organ dysfunction caused by the body's irregular response to infection. Sepsis is the most common cause of death in intensive care units in elderly patients. The effect of CRP, procalcitonin levels and neutrophil/lymphocyte ratio at the time of admission on mortality of internal diseases patients in ICU over 65 years of age are investigated in this study.Methods: The medical records of 207 patients with sepsis hospitalized between June 2018 and May 2019 in the Internal Medicine ICU of Bozyaka Training and Research Hospital were evaluated retrospectively in this cross-sectional study. Demographic data, APACHE II score, SOFA score, presence of systemic disease, CRP, procalcitonin, complete blood count, ICU stay and mortality status were recorded.Results: The mean age of the geriatric patients with 207 sepsis hospitalized in the ICU over a 12-month period was 77.6±8.4 years. The study group consisted of 100 (48.3%) males and 107 (51.7%) females. In the study, 73(35.3%) of the patients died due to sepsis, 134(64.7%) were the surviving group. There was no difference between surviving and deceased patient groups in terms of length of stay (p=0.880). APACHE-II and SOFA scores were found to be statistically different between surviving and deceased patients (p<0.001). The mean procalcitonin level was 3.54±4.77µg/L among the surviving group and 20.83±12.18µg/L among the deceased patient group (p<0.001). The mean CRP was 97.7±77.4mg/L by the surviving group and 136.9±100.8 mg/L by the deceased patient group (p=0.002). The neutrophil/lymphocyte ratio was 7.49±6.83 in the surviving group and 12.73±15.09 in the deceased patient group (p=0.006).Conclusion: Mortality rates of inpatients in ICU were higher than inpatients in other wards. Systematic evaluation of neutrophil/lymphocyte ratio, CRP and procalcitonin results, as well as complete blood count parameters during hospitalization, may be valuable in predicting intensive care outcomes of patients.